JPRN-UMIN000017709已完成未知
A Study of Trastuzumab Emtansine in Patients With HER2-Positive, Recurrent Metastatic Non-Small Cell Lung Cancer - HER2-CS-2 Study
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1)History of intolerance or hypersensitivity to investigational agent or any excipient of the product (2)Current pregnancy or lactation (3)Refusal of use of highly effective contraception (4)Evidence of active pneumonitis during screening or its history, except for pulmonary fibrosis in the radiation field induced by prior thoracic irradiation (5)Left ventricular ejection fraction (LVEF) < 45% by echocardiogram (6)Current severe heart diseases (7)History of myocardial infarction or unstable angina within 6 months of enrollment (8)Current severe, uncontrolled systemic diseases (e.g., clinically significant cardiovascular, pulmonary, or metabolic disease) (9)Patients who have untreated, symptomatic, or uncontrollable CNS metastases (10)Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (11)Current peripheral neuropathy of Grade >/= 3 per the Common Toxicity Criteria for Adverse Events (CTCAE) v. 4.0.3 (12)Patients who have had chemotherapy or radiotherapy within defined weeks prior to entering the study or those who have not recovered from adverse events due to agents administered early (13)Investigational therapy in another clinical study for therapeutic intent administered within 28 days before first study treatment (14)Major surgical procedure or significant traumatic injury within 28 days before enrollment or anticipation of the need for major surgery during the course of study treatment (15)Current known active infection with HIV, hepatitis B, or hepatitis C virus (16)History of other malignancy within the last 5 years (17)Patients who cannot be hospitalized for at least 8 days from day1 in the first cycle Details are documented in the original protocol.
研究者
相似试验
招募中
2 期
Trastuzumab Emtansine in patients with advanced HER2-positive extramammary Paget's disease: a phase ll trialJPRN-jRCTs031200064Funakoshi Takeru16
已完成
2 期
A Multicenter Phase II study of Trastuzumab emtansine for non-small cell lung cancer positive for HER2 exon 20 insertion mutation.Advanced non-small cell lung cancer positive for HER2 exon 20 insertion mutationJPRN-UMIN000035622Kyushu University Hospital22
已完成
2 期
First-line Trastuzumab monotherapy in patients with HER2-positive metastatic breast cancer(MBC)- a phase 2 studybreast cancerJPRN-C000000263H/D study group on Breast Cancer35
已完成
1 期
A Phase Ib study of Trastuzumab emtansine plus S-1 or Capecitabine in patients with previously trastuzumab treated metastatic breast cancerPatients with HER2-positive metastatic breast cancer that has progressed on trastuzumabJPRN-UMIN000018383St Marianna University School of Medicine20
已完成
不适用
The effect of trastuzumab emtansine (T-DM1) to the platelets for HER2-positive advanced breast cancer patientsbreast cancerJPRN-UMIN000014750Hematology and Oncology, Mie University Hospital10